CSRxP Statement on HHS OIG Part D Spending Report
Jun 4, 2018
Today, the Office of the Inspector General at the Department of Health and… Read More
© 2025 CSRXP- All Rights Reserved
Press Release
CSRxP Applauds FDA’s Focus on REMS Abuses
May 31, 2018
The Campaign for Sustainable Rx Pricing released the following statement… Read More
CSRxP Applauds FDA’s Transparency on Brand “Gaming” Tactics
May 17, 2018
The Campaign for Sustainable Rx Pricing released the following statement… Read More
CSRxP on President Trump’s Remarks on Drug Prices
May 11, 2018
The Campaign for Sustainable Rx Pricing released the following statement… Read More
CSRxP Launches TV & Digital Ad Campaign Urging Congress to Pass the CREATES Act
Mar 8, 2018
March 8, 2018 Contact: [email protected] ( 202) 286-4682 The Campaign for… Read More
CSRxP Statement on Nomination of Alex Azar to be Secretary of Health and Human Services
Nov 17, 2017
The Campaign for Sustainable Rx Pricing released the following statement… Read More
Vizient Joins CSRxP as 30th Member of the Coalition
Sep 21, 2017
“We are excited to join CSRxP and be a part of the coalition to achieve reasonable prescription drug prices,” says Jody Hatcher, president, sourcing and collaboration services at Vizient. “Our health care members are facing enormous financial and clinical pressures associated with pharmaceuticals. Read More
37 Signatories Call on Congress to Pass CREATES Act
Sep 20, 2017
37 signatories have called on Congress to pass the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. This coalition represents a broad-based and diverse cross-section of stakeholders – including providers and payers, physicians and consumers, businesses and unions – all of whom have come together in strong support of this important legislation. Read More
CSRxP Calls for Further Action on Rx Prices
Jul 12, 2017
CSRxP spokesman Will Holley releases statement following House passage of FDA user fee legislation. Read More
CSRxP Highlights Big Pharma’s Price Gouging Tactics With New Spot: “The Right”
Jun 19, 2017
“The Right” highlights examples of Big Pharma’s price-gouging tactics, such as Miacalcin’s 3,200% price hike, Daraprim’s 5,000% price hike, and doxycycline’s 9,000% price increase in just six months. These price hikes are part of a longstanding pattern that show no sign of slowing down - in fact, a recent report showed that there were more price hikes in the first quarter of 2017 than there were in the first quarter of 2016. Read More
CSRxP Rolls Out Latest Ad: “Priorities”
May 18, 2017
It's time for Big Pharma to get their priorities straight: American's deserve open and honest prescription drug pricing. Read More
Association for Community Affiliated Plans Joins CSRxP
May 10, 2017
“The people served by ACAP’s members are among the most vulnerable to the out-of-control prices of prescription medications and they have first-hand experience with the effect that Big Pharma’s pricing policies have on real people every day,” said John Rother, Executive Director of CSRxP. Read More